Navigation Links
Calvert Labs Announces the Hiring of Terry Ladd

Terry Ladd (MBA, MA) rejoins Calvert Labs as VP of Business Development

Olyphant, PA (PRWEB) January 28, 2009 -- Calvert Labs, a Calvert Holdings, Inc. company, announced today the hiring of Mr. Terry Ladd as Vice President of Business Development. Mr. Ladd had worked at Calvert Labs from 1994-2003 as Executive Director, Business Development and Marketing.

Mr. Ladd will be responsible for the sales and marketing of preclinical services in North America. With his many years of experience in the drug development/contract research organization field, he brings significant wisdom and experience to the table to help clients attain their goals in drug development in a timely and proper manner.

In addition to earning an MBA from McGill University and an MA from the University of Sherbrooke, Mr. Ladd's well-rounded background includes experience managing the sales, marketing, business development, finance, and administration functions for companies as varied as IMS Health, Guillevin International, Supertel Video Productions and General Electric.

Allan Reiss, President and COO of Calvert Holdings, Inc. remarked: "Although given opportunities to continue a successful career within larger pharma organizations, Mr. Ladd chose to return to a younger, innovative company that has a proven track record within the industry. We are honored that he has chosen to return." Mr. Ladd responded: "I am glad to be back with my former colleagues and look forward to the challenges and successes ahead."

About Calvert Labs:
Regarded by many as the premier IND-enabling contract research organization, Calvert Laboratories has been providing contract nonclinical services for almost four decades. As a global service provider, Calvert Labs' core offerings include toxicology (acute through chronic & carcinogenicity plus reproductive and developmental), pharmacokinetics & ADME, pharmacology, safety pharmacology, immunotoxicology and immunology. Located in northeastern Pennsylvania and easily accessible by major airlines, Calvert Labs provides services to companies in the biotechnology, pharmaceutical, and chemical industrial sectors.

About Calvert Holdings, Inc.
Formed in 1996, Calvert Holdings, Inc. is a privately-held company consisting of a diverse portfolio of companies including the following: Calvert Labs, Calvert Research, Calvert BioCapital, Calvert Creative, Carolina Securities, and Calvert Cafe. Calvert Holdings is a company of people who are passionately engaged in contributing to the future well being of the planet we live on. By analyzing how emerging discoveries and current trends will affect future global needs, we position resources and apply our skills to meet them.


Read the full story at

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Calvert Research and Auburn University Announce Joint Venture
2. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2008 Financial Results
3. Indevus Pharmaceuticals Announces Release of 2008 Annual Report
4. Fadel Partners Announces 13% Growth Despite IT Services Industry Downtrend
5. Cardium Announces Retirement of Director
6. Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2008 Earnings Conference Call
7. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
8. AMDL, Inc. Announces 2009 Financial Guidance and First Quarter Business Objectives
9. Netsmart University Announces Partner Referral Agreement With New York Association of Alcohol and Substance Abuse Providers
10. Rib-X Pharmaceuticals Announces Positive Phase 2 Study Results for Delafloxacin and a $25 Million Financing
11. MAP Pharmaceuticals Announces Completion of Enrollment in Phase 3 Clinical Trial of MAP0004 in Patients with Migraine
Post Your Comments:
Related Image:
Calvert Labs Announces the Hiring of Terry Ladd 
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... announced the funding of a Sponsored Research Agreement ... circulating tumor cells (CTCs) from cancer patients.  The ... in CTC levels correlate with clinical outcomes in ... These data will then be employed to support ...
(Date:6/24/2016)... , ... June 24, 2016 , ... While the majority ... as the Cary 5000 and the 6000i models are higher end machines that use ... height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm ... Mold) microbial test has received AOAC Research Institute approval 061601. , “This is ... last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The ...
Breaking Biology Technology:
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
(Date:3/31/2016)... , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange is ... users of its soon to be launched online site ... ) will also provide potential shareholders ... of DNA technology to an industry that is notorious ...
(Date:3/22/2016)... , March 22, 2016 ... report "Electronic Sensors Market for Consumer Industry by Type ... Others), Application (Communication & IT, Entertainment, Home ... Global Forecast to 2022", published by MarketsandMarkets, ... expected to reach USD 26.76 Billion by ...
Breaking Biology News(10 mins):